Cancer Therapy Using Antiparasitic Medications Guided by Acupuncture Meridian Assessment: A Case Series of Six Patients (2026)

Peer-Reviewed Study · Frederick T. Guilford, S. Yu (Your Energy Systems, Palo Alto, CA) · June 2026

Frederick T. Guilford et al., 2026-06: Case series of six stage IV cancer patients (breast, lung, prostate, glioblastoma, multiple myeloma) treated with antiparasitic and antifungal drugs selected by electroacupuncture meridian assessment, all reported as surviving beyond expectation, with no serious adverse events.

Treatment protocols included combinations of ivermectin, mebendazole, praziquantel, niclosamide, and antifungals, selected based on AMA readings.

Frederick T. Guilford et al., 2026-06: Case series of six stage IV cancer patients (breast, lung, prostate, glioblastoma, multiple myeloma) treated with antiparasitic and antifungal drugs selected by electroacupuncture meridian assessment, all reported as surviving beyond expectation, with no serious adverse events. C3. Study type: retrospective case series, n=6, United States (Your Energy Systems, Palo Alto; patients treated 2011-2022). No comparator, no control group. Doses: not stated in the abstract; drugs combined ivermectin, mebendazole, praziquantel, niclosamide and antifungals, chosen by Acupuncture Meridian Assessment readings; dental infections treated concurrently. Outcomes as reported: breast cancer patient in complete remission 30+ months; myeloma patient alive 14 years with normalised biomarkers; lung cancer patient alive 10 years with negative imaging; both glioblastoma patients with tumour regression, one of whom died from a fall in 2025; prostate patient with PSA fall from 32 to 0.3. Funding: not stated. Disclosures: not stated in the PubMed record. NOTE: co-author Guilford is identified as 'Science Officer, Your Energy Systems', a commercial supplier of the testing technology used to select treatment – a conflict the abstract does not address. Patient-reported outcomes, not independently verified; no imaging or pathology is reported in the abstract. Also filed as IVD-52 (claims C3, C7). Study type: uncontrolled series.